Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 10 systematic review(s)/meta-analysis(es). ^[1-10]
• Cefiderocol-based regimens showed lower all-cause mortality (RR (relative risk)=0.71) and 30-day mortality (RR=0.64) compared to colistin-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections, particularly benefiting bloodstream infection (BSI) patients, while no significant difference was observed for ventilator-associated pneumonia (VAP) patients.
• In the neonatal population, cefiderocol demonstrated a favorable efficacy and safety profile, indicating its potential for use in newborns, infants, and children.
• Cefiderocol monotherapy resulted in lower 30-day mortality compared to combination regimens for carbapenem-resistant Acinetobacter baumannii infections, suggesting its effectiveness as a standalone treatment option.
• There is a noted reduced susceptibility of cefiderocol in treating NDM-positive isolates, reflected by higher minimum inhibitory concentrations (MICs), indicating a need for caution in this subgroup.
• In patients with carbapenem-resistant Acinetobacter baumannii infections, the incidence of acute kidney injury (AKI) did not increase in the cefiderocol-based group compared to colistin-based regimens.
• Cefiderocol was associated with a lower rate of adverse drug reactions (ADRs) compared to the best available therapy (BAT), indicating a favorable safety profile in this population.